Clindamycin Injection

NUMIclid is a potent formulation of Clindamycin Phosphate that falls under the Lincosamides category of therapy. The mechanism of action is a bacteriostatic one, which is binding to the 50S subunit of the bacterial ribosome. Being one of the vital medications in the contemporary management of infectious diseases, NUMIclid offers a quick systemic response to the vulnerable anaerobic and aerobic Gram-positive bacteria. This intervention is effective in stopping bacterial protein production, which avoids the replication and propagation of the pathogen. Another significant use of Clindamycin is that, unlike most of its counterparts, it has been shown to have excellent penetration into bone tissue and can be effectively used to suppress bacterial toxin production, which is essential in treating some severe skin or necrotizing infections.

Composition:
Each 4 ml ampoule contains:

• Clindamycin Phosphate equivalent to Clindamycin 150 mg per ml

• Total Clindamycin content: 600 mg per 4 ml

Therapeutic Class: Lincosamide Antibiotic
(Indicated for the treatment of serious bacterial infections, including respiratory tract infections, skin and soft tissue infections, and pelvic infections)

Medical Uses

The healthcare professional recommends this antibiotic indicates the serious bacterial infections of the following organisms that are susceptible to it:

• Respiratory Tract Infections: These include empyema, anaerobic pneumonitis, and lung abscesses.
• Skin and Soft Tissue Infections: Cellulitis and abscesses Treatment.
• Osteomyelitis: It is the infection of bones and joints that is treated effectively by penetration of the tissues.
• Septicemia: It involves providing systemic protection against bacterial pathogens occurring in the blood.

Directions to Use

NUMIclid has to be administered through Intramuscular (IM) Injection or intravenous (IV) Infusion. In case of IM use, one site should not have more than 600 mg. To be used as few as possible, in the case of IV injection, one should dilute the medicine with a liquid (0.9% NaCl or 5% Dextrose) and inject over at least 10-60 minutes. It must not be administered as an IV bolus, because this may cause heart problems.

Precautions

• GI Health: Extreme cautiousness in patients with a history of gastrointestinal disease, especially colitis.
• Monitoring of the organ: With the longer-term therapy, kidney and liver functional tests should be taken periodically.
• Allergy Profile: It should not be used in patients who are hypersensitive to Clindamycin or Lincomycin.
• Neuromuscular Blockage: It can be used in combination with neuromuscular blocking substances; anesthesiologists and surgeons are to be made aware of its effect.

Possible Side Effects

The adverse reactions could include:

• Gastrointestinal: Diarrhea, abdominal pain, or nausea.
• Dermatology: urticaria, rash, or skin itch.
• Local Reactions: IV infusion involving pain or swelling of the site of injection or thrombophlebitis.

Frequently Asked Questions

Q: Why is NUMIclid a preferred treatment for bone infections such as osteomyelitis?

A: Clindamycin is the only drug that has an outstanding bone-penetrating effect, as it is capable of attaining therapeutic levels in skeletal tissues that most other broad-spectrum antibiotics are unable to penetrate.

Q: Is Numera Life Sciences guaranteed of the stability of the pH of NUMIclid?

A: Yes, our production process incorporates highly sophisticated buffering systems that will hold the drug at a specific pH, thereby assuring stability and a reduced irritation on administration.

Q: Is it possible to use NUMIclid for patients who are allergic to Penicillin?

A: Yes, it is usually a safe and effective replacement for Penicillin-allergic patients because it is also in a different chemical group (Lincosamides).

Q: What does Numera Life Sciences do to ensure that endotoxins have been detected?

A: Each lot of NUMIclid is thoroughly LAL (Limulus Amebocyte Lysate) tested to be pyogen-free and safe in its systemic injection.

Q: Does NUMIclid successfully deal with MRSA (Methicillin-resistant Staphylococcus aureus)?

A: Clindamycin is still used in some clinical settings as an important alternative to the treatment of some types of MRSA in different localized patterns.